Protein marker for myocardial infarction in urine, and applications thereof in diagnosis and prognosis

A myocardial infarction, protein technology, applied in biological tests, instruments, measurement devices, etc., can solve the problem of not being able to detect the disease process and treatment effect in time

Active Publication Date: 2017-08-29
THE INST OF BASIC MEDICAL SCI OF CHINESE ACAD OF MEDICAL SCI
View PDF5 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, plasma troponin T continues to rise for two weeks after myocardial...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Protein marker for myocardial infarction in urine, and applications thereof in diagnosis and prognosis
  • Protein marker for myocardial infarction in urine, and applications thereof in diagnosis and prognosis
  • Protein marker for myocardial infarction in urine, and applications thereof in diagnosis and prognosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0056] Example 1: Detection of myocardial infarction-related proteins in urine

[0057] We used isotope labeling relative and absolute quantification (iTRAQ) labeling differential proteomics to screen for myocardial infarction-related proteins in urine.

[0058] Materials and Reagents

[0059] 1) Instrument: Triple TOF 5600 mass spectrometer (Absciex Company).

[0060] 2) Main reagents: trypsin (Promega); C18 solid-phase extraction column (3CC, 60mg, Waters); 4 standard iTRAQ reagents (Absciex); C18 reversed-phase chromatography column (4.6mm×250mm, C18, 3μm , Waters Corporation).

[0061] 3) Samples: urine from 7 patients with myocardial infarction (within 12 hours of onset and 7 days after treatment) and 7 normal controls, from the Fourth Affiliated Hospital of Jilin University.

[0062] 1.1 Preparation of urine protein

[0063] Urine samples were centrifuged at 3,500 g for 15 min at 4°C to remove cell debris. Take the supernatant, add pre-cooled absolute ethanol (-20°C...

Embodiment 2

[0070] Example 2: Mass Spectrometric Detection of Urinary Protein Antithrombin-III, Complement C3, α-1-Acid Glycoprotein 1, Serum Transferrin and Cathepsin Z

[0071] In order to better carry out the application detection of these differential proteomic analysis results in further large-scale clinical samples, we used targeted mass spectrometry to monitor the differential proteins identified. Multiple Reaction Monitor (MRM) is a target mass spectrometry quantitative analysis technology based on MS / MS signals, which can simultaneously perform absolute and relative quantitative determinations without the assistance of special chemical labels.

[0072] Materials and Reagents

[0073] 1) Instrument: QTRAP 6500 mass spectrometer (AB Sciex Company).

[0074] 2) Main reagents: trypsin (Promega Company); C18 solid-phase extraction cartridge (3CC, 60 mg, Waters Company).

[0075] 3) Samples: urine from 15 patients with myocardial infarction (within 12 hours of onset and seven days af...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a protein marker for myocardial infarction in urine and applications thereof in diagnosis and prognosis, and particularly, relates to applications of identification reagents of following proteins, including antithrombin-III, complement-C3, [alpha]-1-acid glycoprotein 1, serum transferrin, cathepsin Z, and a combination thereof, in preparation of reagents for diagnosis and/or prognosis of the myocardial infarction of patients. Herein, the five proteins have excellent clinical application prospects in the fields of diagnosis of myocardial infarction and detection on diseases status and therapy effects.

Description

technical field [0001] The present invention relates to the field of biotechnology, more specifically to a protein marker of myocardial infarction in urine and its use in diagnosis and prognosis. Background technique [0002] Cardiovascular disease is associated with high morbidity and mortality and accounts for 17% of healthcare expenditure in most industrialized countries. Myocardial infarction is the most important type of cardiovascular disease, leading to a series of complications including cardiogenic shock, ventricular fibrosis, heart failure and recurrent ischemia [1] . According to the European Society of Cardiology, the mortality rate of myocardial infarction is about 6% to 14%. [2] . [0003] In clinical diagnosis, sensitive biomarkers, ECG and imaging techniques are widely used in the diagnosis of myocardial infarction. However, ECG sensitivity is low [2] ; Among biomarkers of myocardial infarction, CK-MB specificity was low (0.591-0.842) [2,3] . Highly se...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): G01N33/68
CPCG01N33/6812
Inventor 孙伟郭正光孙海丹邹莉丽绍晨杨晔宏
Owner THE INST OF BASIC MEDICAL SCI OF CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products